Another study on nucleic acid vaccines demonstrated that a the DNA vaccines encoding NMM (NY-ESO-1/MAGE-A3/MUC1) target antigens and immune-related components successfully elicited cellular immune responses and suppressed tumor growth in C57BL/6 mice, providing a novel approach for tumor vaccine design and laying a foundation for clinical application [65]. This evidence concerns the gene MAGEA3 and neoplasm.